Doximity Gestion
Gestion contrôle des critères 1/4
Le PDG Doximity est Jeff Tangney, nommé en Apr2010, a un mandat de 16.17 ans. La rémunération annuelle totale est $ 17.23M, composée du salaire de 3.5% et des bonus 96.5%, y compris les actions et options de la société. détient directement 27.25% des actions de la société, d'une valeur de $ 1.04B. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2 ans et 10.8 ans.
Informations clés
Jeff Tangney
Directeur général
US$17.2m
Rémunération totale
| Pourcentage du salaire du PDG | 3.48% |
| Durée du mandat du directeur général | 16.2yrs |
| Propriété du PDG | 27.2% |
| Durée moyenne d'occupation des postes de direction | 2yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 10.8yrs |
Mises à jour récentes de la gestion
Recent updates
Seeking Alpha • 3h
Doximity: Everyone Is Focused On The Guidance While Missing The Valuation And AI Stories
Summary Doximity issued conservative FY2027 guidance, projecting 4% revenue growth and a 49% adjusted EBITDA margin, triggering a post-earnings stock selloff. I view the selloff as a temporary dislocation and a compelling buying opportunity for value investors given DOCS's resilient core platform usage. Management emphasized record physician engagement and continued dominance of DOCS's core products despite macroeconomic and regulatory headwinds. AI tools, particularly AI Search and Scribe, are rapidly scaling and positioned as DOCS's next major revenue driver. Read the full article on Seeking Alpha
Mise à jour du récit • Jun 23
DOCS: AI Investment Year And Healthcare Moat Set To Support Reengagement
The updated Doximity analyst price target edges up slightly to $25.42, as analysts balance concerns about slower digital advertising growth, tougher competition, and heavier AI investment against a still supportive longer term rationale. This is reflected in a modestly higher fair value and P/E assumption.
Nouveau récit • Jun 13
High physician usership and impressive AI tools
What I like about Doximity is that there really is a very high viewership / user base of active practicing Physicians in the US and that is not invaluable and definitely could be monetized perhaps more efficiently. I also think that Doximity offers a lot of interesting tools for Physicians a lot of which you’re free and really marketed towards I think Physicians who are more in private practice.Mise à jour du récit • Jun 07
DOCS: Healthcare Moat And AI Investment Year Will Drive Future Engagement
Analyst price targets for Doximity have been reset lower, with the internal fair value estimate moving from $37.77 to $25.15 as analysts factor in slower projected revenue growth, softer profit margins, and a reduced future P/E multiple amid industry wide concerns about digital ad spending, rising competition, and uncertain payoffs from heavier AI investment. Analyst Commentary Street research has turned more cautious on Doximity following its recent results and fiscal 2027 outlook, with many firms cutting price targets and, in several cases, downgrading ratings.
Mise à jour du récit • May 23
DOCS: Heavier AI Spending And Competition Will Drive A Cautious Bearish Outlook
Analysts cut the Doximity fair value estimate from $25.00 to $18.00, citing a wave of price target reductions and ratings downgrades that point to slower expected revenue growth, thinner margins, rising AI investment costs, and tougher digital advertising and healthcare IT competition. Analyst Commentary Street research around Doximity has shifted decisively more cautious, with a cluster of downgrades and lower price targets following the most recent earnings and long term outlook.
Mise à jour du récit • May 09
DOCS: AI Suite And Platform Stickiness Will Support Higher Future Earnings Power
Analysts trimmed their Doximity fair value estimate to $55.00 from $56.00, reflecting reduced revenue growth assumptions, partly offset by expectations for slightly higher profit margins and a marginally richer future P/E multiple following a series of recent price target cuts and mixed rating changes across the Street. Analyst Commentary Recent Street research on Doximity has been mixed, with a cluster of price target cuts and rating changes alongside a handful of more constructive views.Mise à jour du récit • Apr 21
DOCS: Healthcare Moat And AI Tools Will Support Future Engagement
The updated analyst price target for Doximity reflects a modest fair value reduction of about $1.77 per share, as analysts factor in weaker revenue growth visibility highlighted in several recent downgrades and target cuts, while also noting resilient margins and interest in the company’s AI tool suite. Analyst Commentary Recent research on Doximity presents a mix of optimism around the platform and its AI tools, alongside concern about the visibility and durability of revenue growth.Mise à jour du récit • Apr 07
DOCS: Rebased Sentiment And Healthcare Moat Will Support Future Engagement
The updated analyst price target for Doximity moves from about $63.57 to roughly $39.55. This reflects lower modeled revenue growth, profit margins and future P/E multiples, even as several firms highlight the platform's network effects, AI tools and healthcare marketing traction as key long term strengths.Mise à jour du récit • Mar 24
DOCS: AI Tools And Buybacks Will Shape A Cautious Balanced Outlook
Analysts held the Doximity fair value estimate steady at $25.00, while modestly adjusting assumptions after mixed but generally constructive price target moves that highlight interest in the platform's AI tools, network effects, and healthcare marketing exposure. Analyst Commentary Recent Street research on Doximity reflects a split view, with some firms highlighting the medical AI tool suite, network effects and healthcare marketing exposure, while others reset expectations through lower price targets and more neutral ratings.Mise à jour du récit • Mar 09
DOCS: AI Tools And Share Buybacks Will Drive Shares Higher
Doximity's updated fair value estimate has decreased to $56.00 from $68.90, reflecting analysts' reduced price targets from several firms, alongside ongoing support for the company's AI tools and healthcare marketing position. Analyst Commentary Street research on Doximity has been mixed, but there is a clear cluster of bullish analysts who see support for the story in healthcare marketing, AI tools and the company’s position with U.S. physicians.Mise à jour du récit • Feb 23
DOCS: AI Suite And Share Buybacks Will Shape A More Balanced Outlook
The analyst fair value estimate for Doximity has been revised to $25 from $50, reflecting a wave of reduced price targets across several firms, even as some analysts highlight potential from the company’s AI tools and broader healthcare marketing ecosystem. Analyst Commentary Recent research on Doximity shows a split tape, with some firms cutting price targets sharply while others highlight potential upside tied to the company’s tools and healthcare marketing position.Mise à jour du récit • Feb 09
DOCS: Pharma Ad Shift And Share Buybacks Will Drive Shares Higher
Analysts have reduced their Doximity fair value estimate from about US$83 to roughly US$69. This reflects updated expectations for more moderate revenue growth, slightly lower profit margins and a reduced future P/E multiple, even as several firms highlight the company’s strong position in digital healthcare marketing and its expanding product tools.Article d’analyse • Feb 06
Doximity, Inc.'s (NYSE:DOCS) Popularity With Investors Under Threat As Stock Sinks 27%
To the annoyance of some shareholders, Doximity, Inc. ( NYSE:DOCS ) shares are down a considerable 27% in the last...Mise à jour du récit • Jan 26
DOCS: Rebased Sentiment And Strong Moat Will Support Future Engagement
Narrative Update on Doximity The analyst fair value estimate for Doximity has been adjusted from US$65.25 to about US$63.57 as analysts factor in lower target prices, along with continued confidence in the company's moat, market share gains, and higher reported ROI compared with other digital healthcare marketing platforms. Analyst Commentary Recent research on Doximity highlights a mix of optimism and caution as analysts update ratings and price targets while reassessing growth, execution, and risk pricing.Mise à jour du récit • Jan 11
DOCS: Rebased Sentiment And Budget Shifts Will Support Stronger Engagement
Our updated analyst price target framework for Doximity moves fair value from US$71.11 to US$65.25 as analysts recalibrate growth, discount rate and forward P/E assumptions, while still pointing to strengthening platform engagement and expanding tools such as OpenEvidence, as well as what several describe as a defensible competitive position in healthcare professional marketing. Analyst Commentary Recent Street research on Doximity reflects a mix of optimism around the core franchise and its tools such as OpenEvidence, alongside a more cautious reset on valuation and competitive risk.Mise à jour du récit • Dec 26
DOCS: Budget Flush And Pharma Ad Shift Will Drive Shares Higher
We modestly raised our Doximity price target to $83.00 per share from $62.00, as analysts highlight improving long term growth visibility, accelerating video driven revenue momentum, and an increasingly compelling risk reward profile following the recent pullback, despite ongoing debate around pharma digital ad trends. Analyst Commentary Bullish analysts are increasingly highlighting Doximity as a high conviction idea following the post earnings selloff, pointing to a more attractive entry point relative to its vertical software peers.Mise à jour du récit • Dec 12
DOCS: Budget Flush And Ad Shift Will Drive Shares Higher
Analysts have lifted their Doximity fair value estimate to $83.00 from $78.58, reflecting stronger expected revenue growth and improving long term growth visibility, which they believe more than offset lower margin assumptions and a higher required return. Analyst Commentary Bullish analysts highlight that the recent pullback in Doximity shares has created a compelling entry point, with the stock now trading at what they view as an unjustified discount to the broader vertical software peer group.Article d’analyse • Nov 14
Doximity, Inc. (NYSE:DOCS) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
The Doximity, Inc. ( NYSE:DOCS ) share price has fared very poorly over the last month, falling by a substantial 26...Mise à jour du récit • Nov 01
DOCS: Pharma Advertising Shift And AI Expansion Will Drive Measured Opportunity And Risks
Analysts have modestly increased their price target for Doximity, raising the estimate from $70.72 to $71.11 per share. They cite stronger revenue momentum, which is supported by recent upgrades and expectations for higher provider-driven growth.Mise à jour du récit • Oct 18
AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Analysts have raised their price target for Doximity from $69.50 to $70.72. They cited slightly improved profit margin forecasts and increased confidence in the company’s platform engagement as advertising trends evolve.Mise à jour du récit • Oct 04
AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Doximity's analyst price target has increased from $68.67 to $69.50 per share. This change reflects analysts' positive view on strong business momentum, promising AI initiatives, and a conservative outlook for fiscal 2026 revenue growth.Mise à jour du récit • Sep 13
AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Doximity’s price target was raised modestly to $68.67 as analysts pointed to robust Q1 results, AI-driven strategy enhancements, and conservative guidance as drivers of sustained business momentum. Analyst Commentary Bullish analysts cite strong Q1 results and upwardly revised guidance as evidence of solid business momentum.Article d’analyse • Sep 02
At US$67.94, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?
Doximity, Inc. ( NYSE:DOCS ) saw a significant share price rise of 32% in the past couple of months on the NYSE...Article d’analyse • Aug 15
We Think Doximity's (NYSE:DOCS) Profit Is Only A Baseline For What They Can Achieve
NYSE:DOCS 1 Year Share Price vs Fair Value Explore Doximity's Fair Values from the Community and select yours When...Mise à jour du récit • Aug 10
AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Doximity’s fair value outlook has improved as reflected by a higher consensus price target, despite a notable contraction in net profit margin and a rising future P/E multiple signaling higher growth expectations. What's in the News Doximity provided revenue guidance for FY26 of $628–636 million and Q2 FY26 of $157–158 million.Article d’analyse • Jul 08
Getting In Cheap On Doximity, Inc. (NYSE:DOCS) Is Unlikely
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...Article d’analyse • Jun 23
With EPS Growth And More, Doximity (NYSE:DOCS) Makes An Interesting Case
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Article d’analyse • May 17
At US$52.56, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?
Let's talk about the popular Doximity, Inc. ( NYSE:DOCS ). The company's shares saw significant share price movement...Article d’analyse • May 01
Calculating The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Doximity fair value estimate is US$54.31 With US$56.88 share...Article d’analyse • Apr 04
Shareholders Are Optimistic That Doximity (NYSE:DOCS) Will Multiply In Value
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Article d’analyse • Feb 23
What Doximity, Inc.'s (NYSE:DOCS) 28% Share Price Gain Is Not Telling You
Despite an already strong run, Doximity, Inc. ( NYSE:DOCS ) shares have been powering on, with a gain of 28% in the...Seeking Alpha • Feb 10
Doximity Q3 Earnings: Outpacing Even Management's Expectations
Summary I previously rated Doximity, Inc. a buy due to strong Q2 earnings, favorable DCF analysis, and its strategic position in the healthcare industry. Q3 earnings showed continued strength, with DOCS stock up 56% compared to the S&P 500's 2% return since my last analysis. Updated DCF valuation, incorporating management guidance and industry trends, suggests a new price target of $90, indicating 14% upside from today. Doximity's product-market fit remains nearly perfect, with robust revenue growth and efficient cost scaling, supporting a continued buy rating. Read the full article on Seeking AlphaArticle d’analyse • Jan 24
When Should You Buy Doximity, Inc. (NYSE:DOCS)?
Today we're going to take a look at the well-established Doximity, Inc. ( NYSE:DOCS ). The company's stock led the NYSE...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$196m |
| Dec 31 2025 | n/a | n/a | US$239m |
| Sep 30 2025 | n/a | n/a | US$253m |
| Jun 30 2025 | n/a | n/a | US$235m |
| Mar 31 2025 | US$17m | US$600k | US$223m |
| Dec 31 2024 | n/a | n/a | US$201m |
| Sep 30 2024 | n/a | n/a | US$174m |
| Jun 30 2024 | n/a | n/a | US$161m |
| Mar 31 2024 | US$299k | US$295k | US$148m |
| Dec 31 2023 | n/a | n/a | US$138m |
| Sep 30 2023 | n/a | n/a | US$123m |
| Jun 30 2023 | n/a | n/a | US$119m |
| Mar 31 2023 | US$244k | US$240k | US$113m |
| Dec 31 2022 | n/a | n/a | US$119m |
| Sep 30 2022 | n/a | n/a | US$141m |
| Jun 30 2022 | n/a | n/a | US$148m |
| Mar 31 2022 | US$243k | US$240k | US$133m |
| Dec 31 2021 | n/a | n/a | US$107m |
| Sep 30 2021 | n/a | n/a | US$57m |
| Jun 30 2021 | n/a | n/a | US$30m |
| Mar 31 2021 | US$21m | US$240k | US$22m |
Rémunération vs marché: La rémunération totale de Jeff ($USD 17.23M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 6.80M ).
Rémunération et revenus: La rémunération de Jeff a augmenté de plus de 20 % tandis que les bénéfices de l'entreprise ont chuté de plus de 20 % au cours de l'année écoulée.
PDG
Jeff Tangney (53 yo)
16.2yrs
Titularisation
US$17,234,989
Compensation
Mr. Jeffrey A. Tangney, also known as Jeff, Co-Founded Doximity, Inc. in 2010 and has been its Chief Executive Officer and Director since April 2010 and serves as its Chairperson. Mr. Tangney also served a...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Co-Founder | 16.2yrs | US$17.23m | 27.25% $ 1.0b | |
| President | less than a year | pas de données | 0.00045% $ 17.2k | |
| CFO & Principal Financial Officer | less than a year | pas de données | 0.0010% $ 38.2k | |
| Chief Accounting Officer | no data | pas de données | 0.039% $ 1.5m | |
| Chief Technology Officer | no data | pas de données | pas de données | |
| Head of Investor Relations | no data | pas de données | pas de données | |
| General Counsel | less than a year | pas de données | pas de données | |
| Senior Vice President of Engineering | no data | pas de données | pas de données | |
| Senior Vice President of Product | no data | pas de données | pas de données | |
| Senior VP & GM Commercial Products | 3.1yrs | pas de données | pas de données | |
| Senior Vice President of Commercial Operations | 3.1yrs | US$5.21m | pas de données | |
| Chief Commercial Officer | no data | pas de données | pas de données |
2.0yrs
Durée moyenne de l'emploi
53.5yo
Âge moyen
Gestion expérimentée: L'équipe de direction de DOCS n'est pas considérée comme expérimentée (ancienneté moyenne 2 ans), ce qui suggère une nouvelle équipe.
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Co-Founder | 16.2yrs | US$17.23m | 27.25% $ 1.0b | |
| Member of Medical Advisory Board | no data | pas de données | pas de données | |
| Independent Director | 5.8yrs | US$287.10k | pas de données | |
| Independent Director | 15.3yrs | US$291.35k | 0.14% $ 5.2m | |
| Member of Medical Advisory Board | no data | pas de données | pas de données | |
| Member of Medical Advisory Board | no data | pas de données | pas de données | |
| Member of Medical Advisory Board | no data | pas de données | pas de données | |
| Member of Medical Advisory Board | no data | pas de données | pas de données | |
| Member of Medical Advisory Board | no data | pas de données | pas de données | |
| Member of Medical Advisory Board | no data | pas de données | pas de données | |
| Member of Medical Advisory Board | no data | pas de données | pas de données | |
| Independent Director | 6.3yrs | US$282.97k | 0.0091% $ 347.1k |
10.8yrs
Durée moyenne de l'emploi
53.5yo
Âge moyen
Conseil d'administration expérimenté: Le conseil d'administration de la DOCS est chevronné et expérimenté ( 10.8 années d'ancienneté moyenne).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/29 13:14 |
| Cours de l'action en fin de journée | 2026/06/29 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Doximity, Inc. est couverte par 26 analystes. 21 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Vikram Kesavabhotla | Baird |
| Glen Santangelo | Barclays |
| Nisala Weerasuriya | Berenberg |